368 related articles for article (PubMed ID: 34680355)
1. Improved Immunotherapy Efficacy by Vascular Modulation.
Newport EL; Pedrosa AR; Njegic A; Hodivala-Dilke KM; Muñoz-Félix JM
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680355
[TBL] [Abstract][Full Text] [Related]
2. The Tumour Vasculature as a Target to Modulate Leucocyte Trafficking.
Zhao Y; Ting KK; Coleman P; Qi Y; Chen J; Vadas M; Gamble J
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33917287
[TBL] [Abstract][Full Text] [Related]
3. Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade.
Zheng W; Qian C; Tang Y; Yang C; Zhou Y; Shen P; Chen W; Yu S; Wei Z; Wang A; Lu Y; Zhao Y
Front Immunol; 2022; 13():1035323. PubMed ID: 36439137
[TBL] [Abstract][Full Text] [Related]
4. Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges.
Li SJ; Chen JX; Sun ZJ
Cancer Commun (Lond); 2021 Sep; 41(9):830-850. PubMed ID: 34137513
[TBL] [Abstract][Full Text] [Related]
5. BMP9-induced vascular normalisation improves the efficacy of immunotherapy against hepatitis B virus-associated hepatocellular carcinoma.
Han Y; Pan Q; Guo Z; Du Y; Zhang Y; Liu Y; Zhao J; Xu J; Yang J; Ouyang D; Tang Y; Wang Q; Li Y; He J; Yang M; Chen H; Yang C; Yang X; You J; Chen Y; Ren M; Zhu Y; Xia J; Xiang T
Clin Transl Med; 2023 May; 13(5):e1247. PubMed ID: 37132170
[TBL] [Abstract][Full Text] [Related]
6. Tumour vessel remodelling: new opportunities in cancer treatment.
Ganss R
Vasc Biol; 2020; 2(1):R35-R43. PubMed ID: 32923973
[TBL] [Abstract][Full Text] [Related]
7. PAK in Pancreatic Cancer-Associated Vasculature: Implications for Therapeutic Response.
Ansardamavandi A; Nikfarjam M; He H
Cells; 2023 Nov; 12(23):. PubMed ID: 38067120
[TBL] [Abstract][Full Text] [Related]
8. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
9. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
Liu Y; Xun Z; Ma K; Liang S; Li X; Zhou S; Sun L; Liu Y; Du Y; Guo X; Cui T; Zhou H; Wang J; Yin D; Song R; Zhang S; Cai W; Meng F; Guo H; Zhang B; Yang D; Bao R; Hu Q; Wang J; Ye Y; Liu L
J Hepatol; 2023 Apr; 78(4):770-782. PubMed ID: 36708811
[TBL] [Abstract][Full Text] [Related]
10. Low-dose metronomic gemcitabine pretreatments overcome the resistance of breast cancer to immune checkpoint therapy.
Zheng X; Kuai J; Shen G
Immunotherapy; 2023 Apr; 15(6):429-442. PubMed ID: 36880262
[TBL] [Abstract][Full Text] [Related]
11. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan RR; Griffioen AW; Duda DG
Angiogenesis; 2017 May; 20(2):185-204. PubMed ID: 28361267
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
Inthagard J; Edwards J; Roseweir AK
Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
[TBL] [Abstract][Full Text] [Related]
13. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
Georganaki M; van Hooren L; Dimberg A
Front Immunol; 2018; 9():3081. PubMed ID: 30627131
[TBL] [Abstract][Full Text] [Related]
14. The mechanistic immunosuppressive role of the tumour vasculature and potential nanoparticle-mediated therapeutic strategies.
Ileiwat ZE; Tabish TA; Zinovkin DA; Yuzugulen J; Arghiani N; Pranjol MZI
Front Immunol; 2022; 13():976677. PubMed ID: 36045675
[TBL] [Abstract][Full Text] [Related]
15. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.
Zarrabi KK; Narayan V; Mille PJ; Zibelman MR; Miron B; Bashir B; Kelly WK
Ther Adv Urol; 2023; 15():17562872231182219. PubMed ID: 37359737
[TBL] [Abstract][Full Text] [Related]
16. The Angiopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer.
Leong A; Kim M
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33217955
[TBL] [Abstract][Full Text] [Related]
17. Nano drug delivery system reconstruct tumour vasculature for the tumour vascular normalisation.
Liang Q; Zhou L; Li Y; Liu J; Liu Y
J Drug Target; 2022 Feb; 30(2):119-130. PubMed ID: 33960252
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract][Full Text] [Related]
19. Vascular-immuno-phenotypic (VIP) model for locally advanced and oligo-metastatic cancer: A hypothesis.
Swamy K
Med Hypotheses; 2021 Jul; 152():110618. PubMed ID: 34102599
[TBL] [Abstract][Full Text] [Related]
20. Angiopoietin-2-Dependent Spatial Vascular Destabilization Promotes T-cell Exclusion and Limits Immunotherapy in Melanoma.
Park HR; Shiva A; Cummings P; Kim S; Kim S; Lee E; Leong A; Chowdhury S; Shawber C; Carvajal R; Thurston G; An JY; Lund AW; Yang HW; Kim M
Cancer Res; 2023 Jun; 83(12):1968-1983. PubMed ID: 37093870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
